Newsfeeds Archive - Spark Newswire

1 minute read

Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?

June 5, 2:51 PM

Vir Biotechnology reports promising Phase 2 SOLSTICE hepatitis delta trial results, showing high virologic response and ALT normalization rates with tobevibart and elebsiran.

VIR

4 minute read

Why Lands’ End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

By Avi Kapoor

June 5, 1:04 PM

Shares of Lands’ End, Inc. (NASDAQ:LE) fell sharply during Wednesday’s session following first-quarter results. Lands’ End reported quarterly…

AMBC

2 minute read

Ollie’s Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday

By Avi Kapoor

June 5, 10:23 AM

U.S. stocks were mixed, with the Dow Jones index falling more than 100 points on Wednesday. Shares of…

ACLS

3 minute read

Analyst Ratings

Evaluating Vir Biotechnology: Insights From 5 Financial Analysts

By Benzinga Insights

May 24, 1:01 PM

Across the recent three months, 5 analysts have shared their insights on Vir Biotechnology (NASDAQ:VIR), expressing a variety…

VIR

1 minute read

Vir Biotechnology’s SOLSTICE Data To Be Featured At The European Association For The Study Of The Liver Congress 2024

By Benzinga Newsdesk

May 21, 8:30 AM

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the EASL Congress has changed the Company's Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The SOLSTICE data will be

VIR

3 minute read

Analyst Ratings

Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)

By Benzinga Insights

May 7, 9:00 AM

Across the recent three months, 6 analysts have shared their insights on Vir Biotechnology (NASDAQ:VIR), expressing a variety…

VIR

1 minute read

Analyst Ratings

JP Morgan Downgrades Vir Biotechnology: Here’s What You Need To Know

By Benzinga Insights

January 29, 1:00 PM

JP Morgan downgraded its rating of Vir Biotechnology (NASDAQ:VIR) to Neutral with a price target of $9.00, changing…

VIR

1 minute read

Analyst Ratings

HC Wainwright & Co. Maintains Buy Rating for Vir Biotechnology: Here’s What You Need To Know

By Benzinga Insights

January 23, 1:00 PM

HC Wainwright & Co. has decided to maintain its Buy rating of Vir Biotechnology (NASDAQ:VIR) and lower its…

VIR

1 minute read

COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs

By Vandana Singh

December 20, 11:54 AM

COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n

AZN

3 minute read

Vir Biotechnology To Present Late-Breaking Data From Its Ongoing Phase 2 Chronic Hepatitis B And Delta Trials At AASLD’s The Liver Meeting 2023

By Benzinga Newsdesk

November 10, 9:06 AM

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B

VIR